Cargando…

14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model

Alpha-synuclein (αsyn) is the key component of proteinaceous aggregates termed Lewy Bodies that pathologically define a group of disorders known as synucleinopathies, including Parkinson’s Disease (PD) and Dementia with Lewy Bodies. αSyn is hypothesized to misfold and spread throughout the brain in...

Descripción completa

Detalles Bibliográficos
Autores principales: Underwood, Rachel, Gannon, Mary, Pathak, Aneesh, Kapa, Navya, Chandra, Sidhanth, Klop, Alyssa, Yacoubian, Talene A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792107/
https://www.ncbi.nlm.nih.gov/pubmed/33413679
http://dx.doi.org/10.1186/s40478-020-01110-5
_version_ 1783633735315357696
author Underwood, Rachel
Gannon, Mary
Pathak, Aneesh
Kapa, Navya
Chandra, Sidhanth
Klop, Alyssa
Yacoubian, Talene A.
author_facet Underwood, Rachel
Gannon, Mary
Pathak, Aneesh
Kapa, Navya
Chandra, Sidhanth
Klop, Alyssa
Yacoubian, Talene A.
author_sort Underwood, Rachel
collection PubMed
description Alpha-synuclein (αsyn) is the key component of proteinaceous aggregates termed Lewy Bodies that pathologically define a group of disorders known as synucleinopathies, including Parkinson’s Disease (PD) and Dementia with Lewy Bodies. αSyn is hypothesized to misfold and spread throughout the brain in a prion-like fashion. Transmission of αsyn necessitates the release of misfolded αsyn from one cell and the uptake of that αsyn by another, in which it can template the misfolding of endogenous αsyn upon cell internalization. 14-3-3 proteins are a family of highly expressed brain proteins that are neuroprotective in multiple PD models. We have previously shown that 14-3-3θ acts as a chaperone to reduce αsyn aggregation, cell-to-cell transmission, and neurotoxicity in the in vitro pre-formed fibril (PFF) model. In this study, we expanded our studies to test the impact of 14-3-3s on αsyn toxicity in the in vivo αsyn PFF model. We used both transgenic expression models and adenovirus associated virus (AAV)-mediated expression to examine whether 14-3-3 manipulation impacts behavioral deficits, αsyn aggregation, and neuronal counts in the PFF model. 14-3-3θ transgene overexpression in cortical and amygdala regions rescued social dominance deficits induced by PFFs at 6 months post injection, whereas 14-3-3 inhibition by transgene expression of the competitive 14-3-3 peptide inhibitor difopein in the cortex and amygdala accelerated social dominance deficits. The behavioral rescue by 14-3-3θ overexpression was associated with delayed αsyn aggregation induced by PFFs in these brain regions. Conversely, 14-3-3 inhibition by difopein in the cortex and amygdala accelerated αsyn aggregation and reduction in NECAB1-positive neuron counts induced by PFFs. 14-3-3θ overexpression by AAV in the substantia nigra (SN) also delayed αsyn aggregation in the SN and partially rescued PFF-induced reduction in tyrosine hydroxylase (TH)-positive dopaminergic cells in the SN. 14-3-3 inhibition in the SN accelerated nigral αsyn aggregation and enhanced PFF-induced reduction in TH-positive dopaminergic cells. These data indicate a neuroprotective role for 14-3-3θ against αsyn toxicity in vivo.
format Online
Article
Text
id pubmed-7792107
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77921072021-01-11 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model Underwood, Rachel Gannon, Mary Pathak, Aneesh Kapa, Navya Chandra, Sidhanth Klop, Alyssa Yacoubian, Talene A. Acta Neuropathol Commun Research Alpha-synuclein (αsyn) is the key component of proteinaceous aggregates termed Lewy Bodies that pathologically define a group of disorders known as synucleinopathies, including Parkinson’s Disease (PD) and Dementia with Lewy Bodies. αSyn is hypothesized to misfold and spread throughout the brain in a prion-like fashion. Transmission of αsyn necessitates the release of misfolded αsyn from one cell and the uptake of that αsyn by another, in which it can template the misfolding of endogenous αsyn upon cell internalization. 14-3-3 proteins are a family of highly expressed brain proteins that are neuroprotective in multiple PD models. We have previously shown that 14-3-3θ acts as a chaperone to reduce αsyn aggregation, cell-to-cell transmission, and neurotoxicity in the in vitro pre-formed fibril (PFF) model. In this study, we expanded our studies to test the impact of 14-3-3s on αsyn toxicity in the in vivo αsyn PFF model. We used both transgenic expression models and adenovirus associated virus (AAV)-mediated expression to examine whether 14-3-3 manipulation impacts behavioral deficits, αsyn aggregation, and neuronal counts in the PFF model. 14-3-3θ transgene overexpression in cortical and amygdala regions rescued social dominance deficits induced by PFFs at 6 months post injection, whereas 14-3-3 inhibition by transgene expression of the competitive 14-3-3 peptide inhibitor difopein in the cortex and amygdala accelerated social dominance deficits. The behavioral rescue by 14-3-3θ overexpression was associated with delayed αsyn aggregation induced by PFFs in these brain regions. Conversely, 14-3-3 inhibition by difopein in the cortex and amygdala accelerated αsyn aggregation and reduction in NECAB1-positive neuron counts induced by PFFs. 14-3-3θ overexpression by AAV in the substantia nigra (SN) also delayed αsyn aggregation in the SN and partially rescued PFF-induced reduction in tyrosine hydroxylase (TH)-positive dopaminergic cells in the SN. 14-3-3 inhibition in the SN accelerated nigral αsyn aggregation and enhanced PFF-induced reduction in TH-positive dopaminergic cells. These data indicate a neuroprotective role for 14-3-3θ against αsyn toxicity in vivo. BioMed Central 2021-01-07 /pmc/articles/PMC7792107/ /pubmed/33413679 http://dx.doi.org/10.1186/s40478-020-01110-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Underwood, Rachel
Gannon, Mary
Pathak, Aneesh
Kapa, Navya
Chandra, Sidhanth
Klop, Alyssa
Yacoubian, Talene A.
14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model
title 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model
title_full 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model
title_fullStr 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model
title_full_unstemmed 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model
title_short 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model
title_sort 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792107/
https://www.ncbi.nlm.nih.gov/pubmed/33413679
http://dx.doi.org/10.1186/s40478-020-01110-5
work_keys_str_mv AT underwoodrachel 1433mitigatesalphasynucleinaggregationandtoxicityintheinvivopreformedfibrilmodel
AT gannonmary 1433mitigatesalphasynucleinaggregationandtoxicityintheinvivopreformedfibrilmodel
AT pathakaneesh 1433mitigatesalphasynucleinaggregationandtoxicityintheinvivopreformedfibrilmodel
AT kapanavya 1433mitigatesalphasynucleinaggregationandtoxicityintheinvivopreformedfibrilmodel
AT chandrasidhanth 1433mitigatesalphasynucleinaggregationandtoxicityintheinvivopreformedfibrilmodel
AT klopalyssa 1433mitigatesalphasynucleinaggregationandtoxicityintheinvivopreformedfibrilmodel
AT yacoubiantalenea 1433mitigatesalphasynucleinaggregationandtoxicityintheinvivopreformedfibrilmodel